In the news

No Small Plans: Programmable mRNA with Strand Therapeutics

Strand Therapeutics on its Bristol-Myers Squibb LabCentral Golden Ticket Win

Genetic Engineering & Biotechnology News

Cancer Therapeutics Target the Undruggable, Confront Other Bugbears

BioPharm International

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

Inc.

Messenger RNA Took on Covid-19. This Startup Says That's Just the Beginning

YouTube

Strand Therapeutics targeting solid tumors with with its MIT born technology

Business Wire

Strand Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma

Bloomberg

China's Crackdown on Tech a Headache for Investors (Podcast)

MIT Technology Review

He runs a company that’s figuring out the next steps for messenger RNA

Forbes

This Synthetic Bio Startup Raised $52 Million To Make Tumors Reveal Themselves

Fierce Biotech

Strand snags $52M to develop next-gen mRNA meds for cancer

Endpoints

A pair of former MIT researchers think they've unlocked the next generation of mRNA using synbio 'logic circuits'

CNBC Health and Science

Push for patent waivers is 'political theater' and won't solve vaccine shortage, CEO says

Bloomberg

States Hit by Mad Dash for Gasoline Amid Crisis (Podcast)

Business Insider

Germany is not happy with Biden's support for waiving COVID-19 vaccine patents, predicting severe complications

Business Insider

Global leaders want to override COVID-19 vaccine patents to boost production. It probably isn't going to work.

Bloomberg

Building Vaccines to Counter Future Pandemics (Podcast)

Forbes

Breakthrough Bottlenecks: Deploying Cell Therapies Like 5G And The Case For Biotechnology Infrastructure

Reuters

Money, talent flowing into mRNA sector after COVID-19 success

CNBC

Strand CEO Jake Becraft on Squawk Box Asia talks mRNA Vaccines and BeiGene licensing deal

Healthline

How COVID-19 Technology May Help Fight Cancer in the Near Future

BioWorld

Strand Therapeutics weaves together synthetic biology, mRNA

Business Insider

A reinvigorated Alzheimer's treatment and gene-therapy setbacks: 3 winners and 3 losers

Forbes

Declaring War on Infectious Disease: The Case For A Vaccine Manhattan Project

Forbes

From Here To Cured: What Will Post-Pandemic Biotech Look Like?

In Vivo

Lessons From Biotech Entrepreneurs: Pitching Your First-In-Class Innovation

BioSpace

Strand Therapeutics’ mRNA Logic Circuits Enhance Gene Therapy’s Safety, Ease and Controllability

Medium

Becoming a Post-Pandemic Species

The Coronavirus Pandemic

Coronavirus: in search for vaccine, US small firms take a leading role

Med City News

Among Covid-19 vaccine technologies, mRNA represents faster, easier approach, some experts say

Merger Market

Global biotech and pharma leverage pipelines for COVID-19, but no quick win solutions - Analysis

Medium

Strand Therapeutics — Genetically Programming mRNA

FinSME

Strand Therapeutics Raises $6M in Seed Funding

Boston Business Journal

MIT gene-therapy spinout raises $6M

BIOCENTURY

Strand’s smart mRNA

Fierce Biotech

Improving cancer immunotherapy by controlling RNA expression

GEN Edge

RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches

Press release

Business Wire

Strand Therapeutics Appoints Dr. Prashant Nambiar as Senior Vice President, Research and Translational Development

February 08, 2022

Business Wire

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer

August 04, 2021

Business Wire

Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021 Innovator Under 35

June 23, 2021

Business Wire

Strand Therapeutics Raises $52M in Oversubscribed Series A Round

June 23, 2021

Business Wire

Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology

January 11, 2021

Business Wire

Strand Therapeutics Appoints Dr. Dane Wittrup to Scientific Advisory Board and Dr. Mark Frohlich to Newly Formed Clinical Advisory Board

March 11, 2020

Business Wire

Strand Therapeutics Announces $6 Million Seed Financing to Advance its Programmable mRNA Therapeutics Platform

June 04, 2019

contact@strandtx.com
‍

237 Putnam Ave
Cambridge, MA 02139 USA

Copyright 2020. Designed in California
Strand Therapeutics Inc. All Rights Reserved